ABT
ABBOTT LABORATORIES
NYSE · Healthcare · Medical - Devices · US
$102.55
+0.31%Price chart
Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18
Key dataSep 18, 2026
Open$101.73
From 52W high−24.94%
Volume26.99M
Market cap$177.45B
P/E (TTM)33.0x
P/S (TTM)3.8x
Div yield2.42%
Key dataSep 18, 2026
Open
$101.73
From 52W high
−24.94%
Volume
26.99M
Market cap
$177.45B
ValuationView details →
P/E (Fwd)
17.7x
EV/EBITDA
20.6x
P/E (TTM)
33.0x
RSI (14)
38.6
MomentumView details →
1D Return
+0.31%
YTD Return
−17.95%
SummaryUpdated Jun 1, 2026
Abbott Laboratories (NYSE:ABT) is a diversified healthcare company founded in 1888 and headquartered in North Chicago, Illinois. Originally established as a pharmaceutical company by Dr. Wallace Calvin Abbott, the company has evolved over more than 135 years into one of the world's largest healthcare corporations. Abbott operates across four major business segments: Medical Devices, Diagnostics, Nutritional Products, and Established Pharmaceutical Products, serving patients and healthcare providers in over 160 countries worldwide.
Similar companies
Latest newsMore news →
Abbott announced that its FreeStyle Libre 2 received integrated continuous glucose monitoring (iCGM) approval from China's National Medical Products Administration, making it the first and currently only dynamic glucose monitor in China approved to assist adult diabetes treatment decisions.2d agoAbbott's board of directors declared a quarterly common dividend of 63 cents per share, its 411th consecutive quarterly dividend.3d agoAbbott received FDA authorization for its Libre Duo 10 Day system, the world's first dual glucose-ketone sensing biowearable for people with diabetes.26d ago